---
title: "Cellectar Biosciences appoints Andrew Gu to board; Stefan D. Loren to step down, join as consultant"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286815261.md"
description: "Cellectar Biosciences has appointed Andrew Gu as a Class III director and member of the Audit Committee, effective May 18, 2026. Stefan D. Loren will not seek reelection and will transition to a consulting role starting July 8, 2026. Gu's appointment follows a selection by Nantahala, and Loren's decision is not due to any disagreement with the company."
datetime: "2026-05-18T20:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286815261.md)
  - [en](https://longbridge.com/en/news/286815261.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286815261.md)
---

# Cellectar Biosciences appoints Andrew Gu to board; Stefan D. Loren to step down, join as consultant

**Cellectar Biosciences appointed Andrew Gu to its board as a Class III director and Audit Committee member, while Stefan D. Loren informed the board he will not stand for reelection and will provide consulting services starting July 8, 2026.**

**Individual**

Andrew Gu

Stefan D. Loren, Ph.D.

**Role**

Class III director; member, Audit Committee

Class III director (term expiring at 2026 annual meeting)

**Type of Change**

Appointed

Not standing for reelection; consulting agreement

**Effective Date**

May 18, 2026

Not standing for reelection notified May 17, 2026; consulting agreement effective July 8, 2026

**Reason**

Appointment pursuant to Board Designation Side Letter with Nantahala (Nantahala selected Mr. Gu)

Chose not to stand for reelection; decision not due to any disagreement with the Company

**Replacement Info**

N/A

Successor to be determined at annual meeting (term expires at 2026 annual meeting)

**Background Details**

Analyst at Nantahala focusing on biotech investments since June 2021; BS in Economics (Finance) and BA in Neuroscience from University of Pennsylvania (Vagelos Life Sciences & Management Program)

Will provide one-year consulting services promoting Company success; compensated $15,000 per quarter and granted 15,000 stock option at term end; options exercisable for 10 years from grant dates

**Board/Committee Role Changes**

Appointed to Audit Committee

Not disclosed

Original SEC Filing: Cellectar Biosciences, Inc. \[ CLRB \] - 8-K - May. 18, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CLRB.US](https://longbridge.com/en/quote/CLRB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)